IP Library Granted Patent US 9,822,150
Granted Patent B2
US 9,822,150 · App. 14/470,922 · Granted Nov 21, 2017

Patent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,822,150
App. No.
14/470,922
Granted
Nov 21, 2017
Kind
B2
Abstract

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

Claims (12)

1. A method of inducing a bactericidal immune response against a Neisseria meningitidis serogroup B subfamily A strain and against a Neisseria meningitidis serogroup B subfamily B strain in a human, comprising administering to the human an effective amount of a composition, said composition comprising

a) a first lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1, and

b) a second lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2.

2. The method according to claim 1 , wherein the composition further comprises polysorbate-80, aluminum, histidine, and sodium chloride.

3. The method according to claim 1 , wherein the immune response against the Neisseria meningitidis serogroup B subfamily A strain is greater than the immune response against the Neisseria meningitidis serogroup B subfamily B strain.

4. The method according to claim 1 , wherein the immune response against the Neisseria meningitidis serogroup B subfamily A strain in the human comprises a bactericidal titer that is greater than the bactericidal titer against the Neisseria meningitidis serogroup B subfamily B strain in the human.

5. The method according to claim 1 , wherein the composition induces a bactericidal immune response against any one of N. meningitidis serogroup B A22, A56, B24, B44 strains, or any combination thereof.

6. The method according to claim 1 , wherein the composition induces a bactericidal immune response against any one of N. meningitidis serogroup B B24, B16, B44, A22, B03, B09, A12, A19, A05, A07, B153 strains, or any combination thereof.

7. A method of inducing a bactericidal immune response against a Neisseria meningitidis serogroup B strain expressing B153 factor H binding protein in a human, comprising administering to the human an effective amount of a composition, said composition comprising

a) a first lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1, and

b) a second lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2.

8. The method according to claim 7 , wherein the composition further comprises polysorbate-80, aluminum, histidine, and sodium chloride.

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →